For evidence-based clinical long-term follow-up of childhood cancer survivors, risk stratification is required

The National Cancer Survivorship Initiative (NCSI) advocated reorganizing clinical follow-up care in England depending on cancer type and therapy, with levels ranging from Level 1 (assisted self-management) to Level 3 (intensive follow-up) (consultant-led care). The goal of this research was to use a large population-based cohort of pediatric cancer survivors to investigate the risks of major adverse health outcomes related with NCSI Levels of clinical treatment. SPNs—5 percent (two-fold expected), 14 percent (four-fold expected), and 21 percent (eight-fold expected) by 45 years from diagnosis among non-leukaemic survivors assigned to NCSI Levels 1, 2, and 3; non-neoplastic death—2 percent (two-fold expected), 4 percent (three-fold expected), and 8 percent (seven-fold expected); non-fatal infections—2 percent (two-fold expected), 4 percent (three-fold expected); non- As a result, the total cumulative risks of any negative health outcome were 21%, 45%, and 69%, respectively. Despite its simplicity, the risk stratification tool offers evident and substantial discrimination in terms of long-term cumulative and excess risks of major unfavorable outcomes between survivors allocated to various NCSI Levels.